fit-039 and Lymphoma--Primary-Effusion

fit-039 has been researched along with Lymphoma--Primary-Effusion* in 1 studies

Other Studies

1 other study(ies) available for fit-039 and Lymphoma--Primary-Effusion

Article	Year
Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy. BMC cancer, 2023, Jan-20, Volume: 23, Issue:1 Chronic infection with Kaposi's sarcoma-associated herpes virus (KSHV) in B lymphocytes causes primary effusion lymphoma (PEL), the most aggressive form of KSHV-related cancer, which is resistant to conventional chemotherapy. In this study, we report that the BCBL-1 KSHV Topics: Cyclin-Dependent Kinase 9; Herpesvirus 8, Human; Humans; Lymphoma, Primary Effusion; Neoplasms; Sarcoma, Kaposi	2023

Article

Year

Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy.

BMC cancer, 2023, Jan-20, Volume: 23, Issue:1

Chronic infection with Kaposi's sarcoma-associated herpes virus (KSHV) in B lymphocytes causes primary effusion lymphoma (PEL), the most aggressive form of KSHV-related cancer, which is resistant to conventional chemotherapy. In this study, we report that the BCBL-1 KSHV

Topics: Cyclin-Dependent Kinase 9; Herpesvirus 8, Human; Humans; Lymphoma, Primary Effusion; Neoplasms; Sarcoma, Kaposi

2023